In Cohorts B and C, dabrafenib, together with trametinib, was administered to previously treated and untreated advanced-stage NSCLC patients harboring the BRAF exon 15 p.V600E point mutation [128,129]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.